ArticleJournal of neuro-oncology2007
Malignant gliomas actively recruit bone marrow stromal cells by secreting angiogenic cytokines.
Article in Journal of neuro-oncology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
79 citing papers in PubMed, 1 synthesis or guideline pooled it, 185 citations in OpenAlex.
- Mesenchymal stem cells in preclinical cancer cytotherapy: a systematic review.Stem cell research & therapy · 2018Pooled it
- Mesenchymal stem cells and their extracellular vesicle therapy for neurological disorders: traumatic brain injury and beyond.Frontiers in neurology · 2025Review
- Extracellular adenosine oppositely regulates the purinome machinery in glioblastoma and mesenchymal stem cells.IUBMB life · 2024Article
- Integrating Machine Learning and Mendelian Randomization Determined a Functional Neurotrophin-Related Gene Signature in Patients with Lower-Grade Glioma.Molecular biotechnology · 2024Article
- Effects of tumor treating fields (TTFields) on human mesenchymal stromal cells.Journal of neuro-oncology · 2024Article
- On the origin and development of glioblastoma: multifaceted role of perivascular mesenchymal stromal cells.Acta neuropathologica communications · 2023Review
- Mitochondria Transfer from Mesenchymal Stem Cells Confers Chemoresistance to Glioblastoma Stem Cells through Metabolic Rewiring.Cancer research communications · 2023Article
- Effects of glioblastoma-derived extracellular vesicles on the functions of immune cells.Frontiers in cell and developmental biology · 2023Review
- Mesenchymal stem cell therapy for neurological disorders: The light or the dark side of the force?Frontiers in bioengineering and biotechnology · 2023Review
- Article
- Next-Generation Anti-Angiogenic Therapies as a Future Prospect for Glioma Immunotherapy; From Bench to Bedside.Frontiers in immunology · 2022Review
- Growth factors contribute to the mediation of angiogenic capacity of glioma-associated mesenchymal stem cells.Oncology letters · 2021Article
- Mesenchymal stem cells as a double-edged sword in tumor growth: focusing on MSC-derived cytokines.Cellular & molecular biology letters · 2021Review
- Cross talk between mesenchymal and glioblastoma stem cells: Communication beyond controversies.Stem cells translational medicine · 2020Review
- High Adenosine Extracellular Levels Induce Glioblastoma Aggressive Traits Modulating the Mesenchymal Stromal Cell Secretome.International journal of molecular sciences · 2020Article
- Review
- Therapeutic Potential of Mesenchymal Stem Cells for Cancer Therapy.Frontiers in bioengineering and biotechnology · 2020Review
- Mesenchymal stromal cells for bone sarcoma treatment: Roadmap to clinical practice.Journal of bone oncology · 2019Review
- CA10 and CA11 negatively regulate neuronal activity-dependent growth of gliomas.Molecular oncology · 2019Article
- Tropism of mesenchymal stem cell toward CD133Stem cell research & therapy · 2018Article
19 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The transplantation of progenitor cells is a promising new approach for the treatment of gliomas. Marrow stromal cells (MSC) are possible candidates for such a cell-based therapy, since they are readily and autologously available and show an extensive tropism to gliomas in vitro and in vivo. However, the signals that guide the MSC are still poorly understood. In this study, we show that gliomas have the capacity to actively attract MSC by secreting a multitude of angiogenic cytokines. We demonstrate that interleukin-8 (IL-8), transforming growth factor-ss1 (TGF-ss1) and neurotrophin-3 (NT-3) contribute to this glioma-directed tropism of human MSC. Together with the finding that vascular endothelial growth factor (VEGF) is another MSC-attracting factor secreted by glioma cells, these data support the hypothesis that gliomas use their angiogenic pathways to recruit mesenchymal progenitor cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.